| Popis: |
Introduction Pre-operative weight loss of at least 10% of excess body weight has shown to improve both intra and post operative outcomes especially in super-obese patients. Spatz Adjustable Balloon System® (Spatz FGIA, Inc., NY, USA) (SAB3) is the only Intragastric balloon whose volume can be adjusted and left in stomach for a period of 12 months. Its use in super obese patients has not been studied. Aim to retrospectively evaluate the effectiveness of SAB3 in super-obese patients (BMI≥50 kg/m²) as bridge to definitive surgery and report the complications associated with it. Methods Super obese patients who had SAB inserted and completed ≥6 months of follow up were included in the study. The absolute weight loss, mean percent excess weight loss (%EWL) and the% total body weight loss (%TBWL) at 3, 6 and 12 months was recorded from hospital electronic system. Results A total of 60 patients with a mean (±SD) age, initial BMI and weight of 41 years (± 12), 68.59 kg/m² (± 9.57) and 183.45 kgs (± 32.81), respectively had SAB inserted. Data was available on 51, 60 and 31 patients at 3, 6 and 12 months. The mean%EWL at these time points was 10.04 (± 8.36), 10.45 (± 9.85) and 27.92 (27.88).% Patients with >10%TBWL at same time points was 21.6%, 35% and 58%, respectively (table 1 below). 21 (40.4%) patients went on to have a definitive bariatric surgery to date. Complications associated with SAB were abdominal pain in 16.7% (10), severe enough in 6 for unplanned SAB removal, gastroesophageal reflux 13.3% (8), intestinal obstruction 1.7% (1), migration 1.7% (1), deflation in 6.7% (4), nausea/vomiting 12% (7). Conclusion SAB placement in our center was safe, tolerable and achieved the desired weight loss in majority of the super-obese patients. The rate of SAB early removal was in keeping with real world literature. |
